Fasenra Dosage Details: Potencies, Forms, Administration Frequency, and Additional Information
In a significant development for those suffering from severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis, a new brand-name drug called Fasenra has been approved. This biologic, which belongs to the drug class called interleukin-5 (IL-5) antagonist, is prescribed for adults and children aged 6 years and older with severe eosinophilic asthma, as well as for adults with eosinophilic granulomatosis with polyangiitis [1].
Fasenra is administered via subcutaneous injection, usually by a healthcare provider, though trained patients or caregivers may administer it at home using an autoinjector pen [2]. The recommended dose for asthma is 30 mg, given as an injection once every 4 weeks for the first 3 doses, then adjusted to once every 8 weeks. For eosinophilic granulomatosis with polyangiitis, the recommended dose remains the same: 30 mg, given as an injection once every 4 weeks [1].
It's essential to follow the dosage prescribed by your doctor, and if you miss a dose, contact your healthcare professional for instructions. If you take more than the recommended amount of Fasenra, call your doctor right away or contact America's Poison Centers [1].
While the exact dosage for children aged 6 to 11 years with eosinophilic asthma is not explicitly stated, the dosing regimen generally involves subcutaneous injections every 4 weeks for the first three doses, followed by injections every 8 weeks thereafter [3][5]. For precise dosing in pediatric patients, especially children aged 6 to 11, consultation with a specialist (such as a pediatric pulmonologist or allergist) and referring to official prescribing information or updated clinical guidelines is recommended.
Fasenra is not approved for children under 6 years old, and no specific dosing adjustment information for children aged 6 to 11 years is provided in the sources found [5]. Fasenra prefilled syringes are available in two strengths: 10 mg/0.5 mL and 30 mg/mL, while the autoinjector pens come in one strength: 30 mg/mL [2].
It's important to note that Fasenra is a long-term treatment, and it should not be injected around the belly button or in scaly, hard, tender, bruised, scarred, or injured skin. Fasenra is not available in a biosimilar version.
In conclusion, Fasenra offers a promising solution for managing severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. With its convenient administration options and dosing schedule, this biologic could significantly improve the quality of life for many patients. As always, it's crucial to consult with your healthcare provider for personalised advice and guidance.
References:
- Fasenra (benralizumab) for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis)
- Fasenra Dosage
- Fasenra Dosing Regimen for Children
- Fasenra: A New Option for Severe Asthma
- Fasenra: A New Treatment for Severe Asthma
Scientists have developed a new drug called Fasenra, which is approved for both adults and children aged 6 years and older with severe eosinophilic asthma, as well as for adults with eosinphilic granulomatosis with polyangiitis. This drug, a biologic interleukin-5 (IL-5) antagonist, requires a prescription for health-and-wellness treatments and therapies. For precise dosing in pediatric patients, consultations with specialists and referring to official prescribing information are recommended.
